Congenital Hyperinsulinism (CHI) is a condition, which causes people to have unusually high levels of insulin, a hormone, helps control blood sugar levels. Affected people have frequent occurrences of low blood sugar.
In infants and young children, these occurrences are characterized by lethargy, irritability, or difficulty feeding. Repeated episodes of low blood sugar raise the risk for serious complications like breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.
The severity of CHI varies widely among affected individuals, even among members of the same family. About 60% of infants with this disease experience a hypoglycemic episode within the first month of life. Other affected children have hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with CHI can also occur after eating.
Congenital Hyperinsulinism Epidemiological Segmentation
The Epidemiological Segmentation of Congenital Hyperinsulinism in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Cases
- Type-specific Diagnosed Prevalent Cases
- Subtype-specific Diagnosed Prevalent Cases
- Mutation-specific Diagnosed Prevalent Cases
- Diagnosed and Treatable Cases
Congenital Hyperinsulinism Epidemiology
- The total prevalent population of Congenital Hyperinsulinism in 7 MM was 21,852 in 2017.
- Congenital Hyperinsulinism affects both males and females equally.
The therapeutic market of Congenital Hyperinsulinism in 7MM in 2017 was USD 55.76 Million.
Congenital Hyperinsulinism Market Drivers
- Robust Pipeline Activity
- Increasing Awareness of the disease
- Availability of Effective Therapies
Congenital Hyperinsulinism Market Barriers
- Absence of a complete cure for CHI
- Competition among marketed and emerging market
- Lack of Strong Reimbursement Policies
Congenital Hyperinsulinism Emerging Drugs
The emerging drugs of the Congenital Hyperinsulinism market are
- Avexitide (Exendin (9-39))
- Pasireotide (Signifor)
And many others.
Congenital Hyperinsulinism Key Players
The key players in the Congenital Hyperinsulinism market are
- Zealand Pharma
- Xeris Pharmaceuticals
- Eiger BioPharmaceuticals
And many others.